SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech vs. Shorts -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (220)9/16/1999 7:07:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 427
 
Sort of depends on what you call "biotech". If you look hard, you will find my disparaging comments re. LIPO, and you will not find anything remotely approaching a compliment.

And you are aware of my concerns with the other issue, which have nothing to do with current prices and may miss the mark in their entirety. Nonetheless, I was in the one of two correct places to be, on the sidelines (the other being short, like Avalon). Would you use the phrase "Rick 2, Biotech 0"? I think your attempt at balanced reporting is fine, but I'd leave it at Avalon having been correct twice. Hats off to their foresight!

This push/pull is going fine.........
iqc.com

I think that you'll have a difficult time finding a bigger sector bull, but I'm all for shorting 50% of biotechs out of existence.

This is not one of them, but the shorts are winning here too.....
iqc.com



To: Biomaven who wrote (220)9/16/1999 8:32:00 PM
From: Vector1  Read Replies (1) | Respond to of 427
 
Peter,
Avalon is on a roll. They have won a battle on CLTR, however, the war is far from over. Lets see is if the FDA accepts their refile in OCT and the results of the Fludarabine plus Bexxar trial reported at ASH in December. I have my money and reputation riding on CLTR.
v1